Over the years, Open Medicine authors have taken a strong interest in research ethics and particularly the dangers of overly-close or conflicted relationships with pharmaceutical and medical device companies. As you may have intuited from the "closed for submissions" notice on our home page, for a variety of reasons Open Medicine is going to be closing up shop over the next couple of months.
We'll get into the ways that the medical publishing market has changed and the positive ways in which options for open access have blossomed in the years since Open Medicine began, as an upstart and a groundbreaker in the field. Stay tuned over the coming weeks for new, typically topical research articles as well as for our editorial on the reasons we have made this difficult but ultimately, we think, correct decision.
Meanwhile, the issues of access, ethics and transparency that have been drivers of our work have changed but remain critically important and often concerning. Today's article in the Toronto Star on problems with proper and conscientious reporting of side effects in clinical trials is just another piece of evidence that they're issues that need ongoing research, reporting and oversight.
Commenting on this Blog entry is closed.